The approach significantly improved survival in immunocompetent murine models when combined with programmed cell death protein 1 (PD1) decoy immunotherapy and a DC-based GBM vaccine by promoting tumor-specific CD8+ cytotoxic T-lymphocyte (CTL)-mediated killing of GBM cells. This evidence concerns the gene CD8A and neoplasm.